NHS to tackle elderly over-medication with 200 new pharmacists

pharmatimes | May 13, 2019

The NHS has announced plans to recruit an ‘army’ of experts to tackle over-medication in care homes, with many already in place. The pharmacists and pharmacy technicians will prevent care home residents from being given too many medicines as part of a package of measures to improve older people’s health and care in the NHS Long Term Plan. Currently, care home residents are prescribed an average of seven medicines a day, with many taking 10 or more, costing the NHS an estimated £250 million each year. Due to concerns about the over-medication, the 200 new clinical pharmacists and pharmacy technicians will support care home residents to improve their quality of life, cut hospital stays and reduce over-medication.

Spotlight

Before placing a medical device on the European market, manufacturers need to produce technical documentation providing evidence of conformity with the relevant legislation. Technical documentation needs to be in compliance with the Medical Devices Directive (MDD) 93/42/EEC or the Active Implantable Medical Devices Directive (AIMDD) 90/385/EEC (referred to as ‘MDD/AIMDD’ hereafter).

Spotlight

Before placing a medical device on the European market, manufacturers need to produce technical documentation providing evidence of conformity with the relevant legislation. Technical documentation needs to be in compliance with the Medical Devices Directive (MDD) 93/42/EEC or the Active Implantable Medical Devices Directive (AIMDD) 90/385/EEC (referred to as ‘MDD/AIMDD’ hereafter).

Related News

PHARMACY MARKET

LIDDS Next Step with NanoZolid® formulated docetaxel

LIDDS AB | February 22, 2022

LIDDS AB announced that the next step in the development of NanoZolid®-formulated docetaxel will be to conduct a short clinical study to understand the immunological effects observed in the Phase I clinical study NZ-DTX-001. In the NZ DTX-001 study, activation of systemic inflammatory biomarkers was observed, which can provide improved conditions for treatment with so-called checkpoint inhibitors and result in treatment effect in non-injected tumors. In the clinical phase I study with nanodotax, which ended in October 2021, an activation of systemic inflammatory biomarkers was observed, which may open up the possibility of a combination therapy with so-called checkpoint inhibitors in cancer immunotherapy. Clinical studies have shown that systemically administered docetaxel significantly improves the response to treatment with checkpoint inhibitors. If LIDDS can show a similar effect with locally administered nanodotax but without systemic side effects, which risk inhibiting the specific immune response against the tumors, both improved efficacy and safety could be achieved. LIDDS has shown in preclinical studies that locally administered nanodotax has as good effect as systemically administered docetaxel but without systemic side effects. In order to provide a better foundation for decision-making in the clinical development of nanodotax, LIDDS has chosen to take over the sponsorship of the previously approved investigator driven trial on prostate cancer patients. The study provides an important analysis opportunity of the immunological response as the included patients will have their prostate surgically removed, which can be analyzed in detail. The study is planned to be conducted at one clinical site and is expected to include ten patients. “Based on the exciting activation of immunoregulatory molecules we saw in the Phase I study, it is important to confirm the mechanism of action of nanodotax. The increased understanding of the mechanism will more promptly lead us to the right form of treatment and patient group. The results may possibly also pave the way for more effective combination treatments, which is considered crucial for the commercial positioning of nanodotax and it justifies a further study” Nina Herne, CEO of LIDDS In December 2021, LIDDS announced the top-line data of the clinical Phase I study NZ-DTX-001. It was demonstrated that NanoZolid® in combination with docetaxel was safe and well tolerated, reaching the primary endpoint of the trial. The data also showed that the systemic docetaxel exposure was low and that activity in injected lesions was observed. Patients receiving docetaxel showed activation of systemic inflammatory biomarkers that are considered important for efficient recruitment and activation of immune effector cells and for creating a good environment for treatments with immune-modulating drugs such as check-point inhibitors. The information was submitted for publication, through the agency of the aforementioned contact person, on February 21, 2022 at 16.30 CET. LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology NanoZolid®. NanoZolid® is a clinically validated drug development technology and superior in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid is combined with antiandrogens and in-house development projects in clinical and preclinical phase for cytostatics and immunoactive agents. LIDDS (LIDDS) shares are listed on Nasdaq First North Growth Market. Redeye AB, certifiedadviser@redeye.se, +46 (0)8 121 576 90, is a certified adviser to LIDDS.

Read More

PHARMACY MARKET

Lilly Collaborates with Samsung to boost COVID-19 antibody manufacturing amid supply concerns

Lilly | November 18, 2020

Seven days after Eli Lilly won a FDA crisis approval for its COVID-19 counter acting agent, worries over restricted supplies are as of now springing up, and the organization is getting an accomplished assembling accomplice to help with the worldwide scale-up. Under a drawn out arrangement with Samsung Biologics, the organizations are set to "incredibly quicken the worldwide gracefully" for Lilly's COVID-19 antibodies, Samsung Biologics said in a delivery. Lilly would like to make up to 1 million dosages this year and a lot more in 2021, Reuters reports. The accomplices entered an underlying assembling association back in May, and, from that point forward, Samsung created a first clump of dynamic drug fixing in spite of struggling getting crude materials. The organizations took care of the tech move in under a quarter of a year, a consequence of routine collaborations between specialists at both medication creators, Samsung Biologics said. Lilly's bamlanivimab scored a FDA crisis use approval a week ago in gentle to-direct COVID-19 patients who are at a high danger of advancing to extreme illness. The FDA said the medication isn't approved in hospitalized patients, and Lilly is instructing imbuement inside 10 days concerning manifestation beginning. Before the crisis gesture, the organization entered a flexibly manage the U.S. government for 300,000 dosages at $1,250 per portion. All things considered, the stock could last only multi week dependent on current disease patterns, Reuters reports. While the arrangement incorporates a possibility for additional portions, specialists told the news administration they expect the medications will turn into a business drug sooner or later.

Read More

PHARMA TECH

Bruker Launches New timsTOF-based MALDI PharmaPulse® Solution for Label-free HTS in Drug Discovery

Bruker Corporation | February 07, 2022

At the SLAS2022 International Conference and Exhibition, Bruker Corporation announced the launch of its timsTOF MALDI PharmaPulse® (timsTOF MPP) system, a groundbreaking new high-end solution for unbiased, deep HTS and uHTS based on label-free mass spectrometry. The new timsTOF® MPP is now the flagship of Bruker´s MALDI PharmaPulse product family which became a game changer in the HTS market with the launch of the rapifleX MPP, a MALDI-TOF-based label-free uHTS solution, in 2017. The timsTOF MPP features the extreme speed and proven robustness of MALDI and, for the first time ever in HTS, takes advantage of Bruker´s innovative Trapped Ion Mobility Spectrometry (TIMS) technology. TIMS enables rapid gas-phase separation of isobars, and even isomers, by exploiting the molecular collisional cross-section. This, in combination with routine 50,000 mass resolution at full speed with QTOF-MS detection enables revolutionary levels of assay specificity at HTS speed. The timsTOF MPP features a dual MALDI / ESI ion source with industry-leading 10 kHz smartbeam™ 3D laser to enable uHTS compatible speed and throughput, and is available with the unique MALDI-2 option for an expanded chemical space. As part of the timsTOF MPP solution, the new MALDI PharmaPulse® 2023 software supports a broad range of HTS applications for drug discovery. Its automation interface allows for timsTOF MPP integration in high throughput environments and works in concert with common scheduling software packages from various vendors. Furthermore, MPP 2023 features seamless transfer of data and results to downstream analysis software, e.g., to Genedata Screener®. “The timsTOF MPP is a major step towards higher efficiency in drug development as it reduces the need for orthogonal assays and technologies by its significantly higher HTS information content and, thus, further lowering of the false discovery rate (FDR). The high specificity of TIMS in combination with high resolution QTOF-MS detection is a great advantage for a broad variety of screening workflows such as binding assays, phenotype screening and biochemical and cell-based mechanistic assays. Furthermore, timsTOF MPP offers great potential for CCS-enabled near real-time synthesis screening in high-throughput experimentation (HTE) chemistry, paving the way to newly designed drug molecules. Bruker´s recently introduced laser based post-ionization technology (MALDI-2), can serve as a highly capable tool to expand the accessible analyte space adding to the versatility of this innovative platform.” Dr. Meike Hamester, Director of Label-free BioPharma Technologies at Bruker Daltonics About Bruker Corporation (Nasdaq: BRKR) Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics.

Read More